LTR Executes U.S. Commercial Agreement with Strive
Filed with ASX · · 4 pages · English
Summary by 6ix AI
LTR Pharma Limited has executed a definitive commercial agreement with Strive Specialties Inc. for the manufacturing and distribution of ROXUS in the United States. This agreement converts a previously announced term sheet into a comprehensive framework for manufacturing, compounding, and fulfillment operations. The partnership aims to support the U.S. commercialization strategy alongside another agreement with Shed for patient acquisition. LTR Pharma will now focus on technology transfer and operational implementation ahead of the commercial launch.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from LTR Pharma
- LTR Executes Definitive U.S. Commercial Agreement with Shed
- Response to ASX Aware Letter
- LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS
- LTR Secures First U.S. Commercial Agreement for ROXUS
- SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations
Later from LTR Pharma
- SPONTAN Real-World Study Reports 93% Response
- FY26 Results Announcement
- SPONTAN Phase II Final Results
- First ROXUS Prescriptions Fulfilled in the United States
- Australian-Developed ED Nasal Spray Now Being Prescribed in the U.S.
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma